Breaking innovation transformation! PharmaCon's 6th Chemical Drug Research and Development Forum was rebooted in October.

Introduction: China's chemical pharmaceutical companies pain point, but also need to be targeted to solve.
with the change of national medical reform policy and the normalization of centralized procurement of national drugs, Chinese chemical and pharmaceutical enterprises have gone through a life-and-death examination.
the 2020 national pharmaceutical policy and documents, no doubt also to the industry towards high-quality development direction.
China's chemical pharmaceutical companies face many challenges on the road of increasing investment in innovation, implementing the combination of imitation and transforming innovative enterprises: How to meet the regulatory requirements of chemical drug regulations that are constantly being updated and iteratively updated? How to meet the clinical needs of differentiated new drug projects? In the AI era, how can target validation and compound screening for innovative drugs be accelerated? How to break through the technical bottleneck and industrialization challenge of improved new drugs and high-end preparations? How to balance low-cost and efficient product development? How to coordinate clinical and preparation development optimization? ...... In October, the China Chemical and Pharmaceutical Industry Association, in association with Shangtu Information, will hold the 6th China International Chemical Drug Research and Development Forum at PharmaCon2020, divided into 3 major topics, inviting more than 40 leading enterprises in new drug research and development, regulatory experts and scientists, will focus on a class of innovative drugs, Class 2 improved new drugs and other categories, analysis of the new version of drug management methods under a series of new chemical regulations, explore the new target chemical drug screening of cutting-edge innovative research and development, share high-end preparation prescription, process and quality control and evaluation of the leading industrialization practice, and then explore the Chinese characteristics of the new drug transformation and upgrading of the research and development road! PharmaCon2020 Wonderful Settings: PharmaCon Previous Guest Review (partial): Liu Chun, Director of the Chemical Medicines Department of the Registration Division of the State Food and Drug Administration; Pan Guangcheng, Executive Director of the China Chemical and Pharmaceutical Industry Association; Sun Huimin, Director of the Chemical And Pharmaceutical Inspection Institute of the Chinese Academy of Sciences; Xu Mingzhe, Deputy Director of the Chemical And Drug Inspection Institute of the China Food and Drug Inspection Institute; Chief Expert in Chemical Drug Inspection of the Chinese Academy of Sciences; Zhang Qiming, Researcher of the Chinese Academy of Sciences, Deputy Chairman of the Special Committee of the Pharmacopoeia Commission; Hugues Malonene, Director of listing authorization of the Federal Medicines and Health Products Agency of Belgium; Ridha Beliba, Clinical PK Head of the French Drug Administration, EU EMA Expert; Jan Welink, Chairman of PKWP of the EU Working Group on Drug Metabolic Dynamics; Yang Yongjian, Chief Expert, Shanghai Food and Drug Inspection Institute Director, Center for Drug Metabolism Research, Shanghai Institute of Pharmaceutical Research; Pavel Farkas, Senior Director of Clinical Development, TEVA; He Xiaoxuan, Director of Materials Analysis Science, Bollinger Ingham U.S. Research and Development Center; Stefan Horkovics-Kovats, BE Specialist Sanders (Austria); Shen Lingjia, Former Deputy General Manager, Jiangsu Hengrui Pharmaceutical Co., Ltd. Du Jingming, Senior Vice President, CMC, Hu Yanjing, former Vice President and Chief Chemist of Beida Pharmaceuticals, President and CEO of Garcos Research and Development, Dong Ping, Technical Director of Zheng Tianqing Nanjing Research Institute, Brian Berry, Senior Director of Science and Law, United Asia Laboratories Co., Ltd. More guest information can be found on the PharmaCon2020 website: The five-time successful PharmaCon Conference is dedicated to building a tri-party technology exchange and cooperation platform for Chinese chemical/innovative pharmaceutical companies, domestic and foreign regulatory agencies, and the world's leading chemical pharmaceutical companies.
PharmaCon as the annual brand chemical forum, has provided a cumulative exchange platform for 2000 plus delegates and 120 plus exhibitors, greatly promoting the industry's upstream and downstream industrial chain cooperation and development.
PharmaCon2020 Speaker Hot Collection: Speech Summary / Paper Contribution, assessed and confirmed by the Organizing Committee guests will enjoy the following benefits: to obtain a free full VIP participation certificate, during the meeting buffet luncheon, during the meeting exclusive VIP lounge, the organizing committee official publicity and promotion.
: pharmacon@bmapglobal.com Forum open keynote speech, product display, cooperation invitation and other forms, all-round for you to show new drug research and development innovation program! PharmaCon2020 sincerely welcomes you to attend this forum, through face-to-face exchanges, you will get the latest information, find new partners, discover new ideas, promote the development of new chemical drug research and development in China.
bird tickets are in hot demand! Group special offers: full 3 people give another 1 equal rights and interests to attend the ticket! Single ticket purchase limited-time special 10% discount, enter the official website using the coupon code drth to enjoy the discount! Sweep code into the forum official website to seize preferential seats for more information, please contact the organizing committee consultation: 18017939885 e-mail: pharmacon@bmapglobal.com forum official website: